Clene Inc. Common Stock

Day range

$3.78 – $3.92

Open

$3.92

Prev close

$3.88

Volume

28.24K

Market cap

$55.15M

Shares out

12.99M

P/E

—

P/S

279.95

P/B

-2.23

P/FCF

—

ROE

159.5%

ROA

-171.5%

Debt/Equity

-0.76

Div yield

0.00%

As of Oct 23, 2026

• Capital allocation updateSep 16, 2026

  The Company expects to use the net proceeds from the offering, together with its existing cash, for expenses primarily related to general corporate purposes, including to fund the effort supporting the continued regulatory dialogue and preparation of regulatory filings and a new drug application for the Company's lead drug candidate, CNM-Au8, including expanded access protocols, potential future commercialization efforts and manufacturing expansion.

• Investor presentationAug 10, 2026

  On August 10, 2026, Clene Inc. (the "Company") released an updated corporate presentation (the "Corporate Presentation") on its website, invest.clene.com. A copy of the presentation is furnished as Exhibit 99.1 to this Current Report on Form 8-K.

• Credit facilityMay 14, 2026

  On May 11, 2026, Clene Inc. entered into the second amendment to the amended and restated senior secured convertible promissory notes with Kensington Clene 2024, LLC, 4Life Research, LLC and La Scala Investments, LLC. Pursuant to the Second Amendment, the maturity date was extended to the earlier of August 13, 2027 or a change in control, and monthly aggregate principal and accrued interest payments of $1,000,000 per month were deferred, with the full balance due on the Maturity Date.

• Public offeringMay 5, 2026

  On May 5, 2026, Clene Inc. (the "Company") entered into an underwriting agreement (the "Underwriting Agreement") with Canaccord Genuity LLC as underwriter, pursuant to which the Company agreed to issue and sell an aggregate of 1,000,000 shares of the Company's common stock, par value $0.0001 per share ("common stock"), at an offering price of $7.00 per share. Canaccord Genuity LLC is acting as the sole bookrunner in the offering, and Maxim Group LLC and D. Boral Capital LLC are acting as financial advisors.

• Clinical trial resultsMay 4, 2026

  The planned NDA submission will be supported by NfL biomarker and clinical data from the Phase 2 HEALEY ALS Platform Trial and its open-label extension, as well as the Phase 2 RESCUE-ALS Trial, and the National Institute of Health-sponsored Expanded Access Protocol for CNM-Au8. Supporting data include reductions in plasma NfL associated with longer survival in the open-label extension and additional clinical outcomes.

Days to cover

7.5

Short interest

880.69K

Avg volume

117.42K

As of Sep 30, 2026 · reported to FINRA twice monthly.

• Clene Announces New Drug Application Submission to FDA for CNM-Au8 for the Treatment of ALS
  positiveGlobeNewswire Inc.· Oct 19, 2026
• Clene Issues Stockholder Letter Highlighting Upcoming CNM-Au8® 2026 Catalysts
  positiveGlobeNewswire Inc.· Feb 24, 2026
• Clene to Provide CNM-Au8® ALS Program Update
  neutralGlobeNewswire Inc.· Dec 2, 2025
• Clene Posts 70% Revenue Drop in Q2
  neutralThe Motley Fool· Aug 14, 2025
• Clene to Present at the H.C. Wainwright 26th Annual Global Investment Conference
  positiveGlobeNewswire Inc.· Sep 3, 2024